Although the treatment landscape is continually evolving, resulting in updates to treatment guidelines, adherence to recommendations remains low in clinical practice [8,18,37], demonstrated by suboptimal CKD screening in patients with T2D and consistent underutilization of ACEis/ARBs, SGLT-2is, MRAs, and GLP-1 RAs in eligible patients [7,8,49]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.